All News
#OP0049 corevitas observational registry: ax-SpA patients showed younger age, more males, greater spinal pain, more exposure to cs- or bDMARD but similar fatigue and work impairment compared to ax-PsA #EULAR2021 @RheumNow
Paul Studenic Stiddyo ( View Tweet)
#EULAR2021: If we review ASAS40 response from infliximab to tofacitinib, then there has not been much evolution in efficacy of therapy for SpA in the past 20 yrs. This suggests we haven't been looking at the right endpoint in measuring efficacy! MDA instead!
@RheumNow https://t.co/E61yb97CRN
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#Eular2021: There is no diagnostic criteria for nr-AxSpA, but there is a diagnostic approach that entails collecting clinical information and imaging to visualize inflammation or post-inflammatory changes of the axial skeleton. @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#Eular2021: Do you start a bDMARD for nr-AxSpa without objective evidence of inflammation (elevated CRP, negative structural damage on MRI)? @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#Eular2021 "Just because they do not have nonradiographic-AxSpa, it does not mean that the disease burden is less (compared to radiographic-AxSpa)!" Dr. Atul Deodhar @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Crosssectional multicentre study clusters phenotypes of #spondyloarthritis differentiating two types: axial and peripheral, Fitted well to either diagnoses of ax-SpA or #PsA. Still overlap of features like arthritis, dactylitis and enthesitis exists. #OP0047 #EULAR2021 @RheumNow https://t.co/sru9bT4mla
Paul Studenic Stiddyo ( View Tweet)
Using data of the E3N prospective observational study - including 98995 women - passive smoking in childhood or adulthood could be found as risk factor for #RA and potentially earlier onset
#OP0012 #EULAR2021 @RheumNow https://t.co/58DJ8lZzfV
Paul Studenic Stiddyo ( View Tweet)
Novel Results from the @rheum_covid register in #RA patients presented by @jeffsparks #OP0006
Higher risk for patients on rituximab or on JAK inhibitors for hospitalisation & ventilation or death after #COVID19 infection compared to TNFi users. #EULAR2021 @RheumNow https://t.co/40h5zVpxAO
Paul Studenic Stiddyo ( View Tweet)
#Eular2021: Is AS & nr-AxSpA the same disease? The current consensus is that they are the two ends of the spectrum -- same disease! @RheumNow https://t.co/r0fTtp3Uip
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021 M:F ratio in nr-AxSpa is 1:1. The baseline features between r-AxSpa and nr-AxSpA is similar with equal burden of disease. @RheumNow https://t.co/tm9Y6OB5TY
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
MD, PhD ✅
Nice milestone in a career
Excited for the future 😎 https://t.co/cYlBEUXwQ5
Aurelie Najm AurelieRheumo ( View Tweet)
Our meta-analysis on IA GC effects on pain and function in knee OA vs. controls at different time points: short term superiority of IA GC, medium term effect is no longer significant apart vs PBO and long term IA GC non superior vs controls. #EULAR2021 @RheumNow #POS1099 https://t.co/mQ0bMF03IT
Aurelie Najm AurelieRheumo ( View Tweet)
Data from E3N-EPIC cohort: passive tabagism in both childhood (HR 1.42 95CI [1.07 to 1.88]) and adulthood (HR 1.27 95CI [1.02 to 1.57]) associated with higher risk of RA in non smoking women (adjusted on age passive smoking educational level BMI)
#EULAR2021 @RheumNow #OP0012
Aurelie Najm AurelieRheumo ( View Tweet)
Towards personalized therapy in RA with @MeganHanlon4's work: the synovial macrophage sub-population CD206+CD163+ is significantly enriched in RA synovial tissue, correlated with disease activity and baseline levels predict response to therapy.
#EULAR2021 @RheumNow #OP0028
Aurelie Najm AurelieRheumo ( View Tweet)
Insights in RA and colon:
Naïve RA patients
-higher degree of intestinal permeability vs age and sex matched ctrls in colonic biopsies
-higher serum levels of bacterial translocation markers (LBP and CD14s); reduced in resp to DMARDs. #EULAR2021 @RheumNow #OP0035 @ClaireDaien
Aurelie Najm AurelieRheumo ( View Tweet)
Can we taper IV belimumab in #SLE? Dr Fredi reported 14/48 (29%) extended tx to at least 5-weekly after 12mo of tx. No worsening C3/C4 & PGA but interestingly #steroid and SLEDAI ⬇️. More works needed to identify suitable pts for taper and regime #EULAR2021 #POS0107 @RheumNow https://t.co/Gwe7mPWPdY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In a UK 🇬🇧 study of newly diagnosed #SLE, Dr Yee reported higher damage in the first 3yrs but then stabilised. Death rate in the first 12yrs had improved to 4.8% (mostly heart disease and infection) but could still occur early (within 5yr diagnosis) #EULAR2021 #POS0111 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In patients with #SLE who attained LLDAS, a retrospective cohort study by Dr Cunha identified predictors of flares including anti-RNP +ve, concomitant immunosuppressant and oral prednisolone. Important to account these during follow-up #EULAR2021 #POS0105 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Hello @IainBMcInnes1, and thanks for your president's welcome to the #EULAR2021 portal!
Clean and straightforward, I like it. No tour required! @eular_org @RheumNow https://t.co/RDRl4FhEZj
David Liew drdavidliew ( View Tweet)
Starting Thursday we'll be covering EULAR. Tune in for coverage on KOL perspective highlights, clinical trial highlights and much more. https://t.co/L7ryiQ5HdV
Dr. John Cush RheumNow ( View Tweet)